Murali Chakinala, MD
Pulmonary Disease · Saint Louis, MONPI 1407872724
Payments from drug & device makers
Across 553 payments — averaging $4411.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$1.1M
- Janssen Research & Development, LLC$431K
- Medtronic$302K
- United Therapeutics Corporation$288K
- Actelion Pharmaceuticals, Ltd$215K
- Bayer$45K
- plus $54K from 11 others
What the payments were for
- Consulting fees$134,24378%
- Speaking & faculty fees$3,9602%
- Travel & lodging$24,08614%
- Food & beverage$9,9346%
- Education$130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 110 | $1,105,925 |
| Janssen Research & Development, LLC | 114 | $431,300 |
| Medtronic(2 entities) | 20 | $301,828 |
| United Therapeutics Corporation | 147 | $287,580 |
| Actelion Pharmaceuticals, Ltd | 32 | $214,624 |
| Bayer | 55 | $44,593 |
| Actelion Pharmaceuticals US, Inc. | 36 | $26,242 |
| Insmed, Inc. | 6 | $7,200 |
| Sumitomo Pharma America, Inc. | 2 | $6,788 |
| Chiesi USA, Inc. | 6 | $5,475 |
| Janssen Scientific Affairs, LLC | 1 | $5,375 |
| Alnylam Pharmaceuticals Inc. | 9 | $1,628 |
| Sandoz | 11 | $614 |
| Liquidia Technologies, Inc. | 1 | $140 |
| Penumbra, Inc. | 1 | $136 |
| AstraZeneca | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TYVASO$20,022
- Adempas$18,756
- UPTRAVI$18,285
- OPSUMIT$15,255
- ORENITRAM$13,611
- WINREVAIR$11,654
- REMODULIN$10,111
- KEYTRUDA$465
- TREPROSTINIL$233
- YUTREPIA$140
- Indigo System$136
- All-In-One$118
How this compares
$2,439,479 in reported general payments places this provider in the 95th percentile of 295 pulmonary disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 829 | $10,519,049 |
| AdempasRiociguat | 422 | $5,892,674 |
| Tyvaso DpiTreprostinil | 155 | $3,921,312 |
| Orenitram ErTreprostinil Diolamine | 165 | $2,760,452 |
| UptraviSelexipag | 117 | $2,752,398 |
| WinrevairSotatercept-Csrk | 126 | $2,138,783 |
| Ambrisentan | 485 | $1,520,450 |
| LetairisAmbrisentan | 86 | $1,056,016 |
| Tadalafil | 594 | $480,912 |
| AdcircaTadalafil | 48 | $236,700 |
| RemodulinTreprostinil Sodium | 15 | $194,104 |
| TreprostinilTreprostinil Sodium | 11 | $158,312 |
| JardianceEmpagliflozin | 133 | $99,046 |
| VeletriEpoprostenol Sodium | 12 | $94,881 |
| Sildenafil Citrate | 340 | $91,668 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi, Bosentan | $26,242 | $13,325,477982 claims |
| BayerAdempas | $44,593 | $5,892,674422 claims |
| MerckWinrevair | $1,105,925 | $2,138,783126 claims |
| United Therapeutics CorporationAdcirca, Remodulin | $287,580 | $430,80463 claims |
| SandozTreprostinil | $614 | $158,31211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 295 pulmonary disease providers in Missouri.
Other pulmonary disease in Saint Louis
- Joseph OjileSaint Louis$2.1M
- Jeffrey HarrisSaint Louis$1.1M
- Kaharu SuminoSaint Louis$1.1M
- Tonya RussellSaint Louis$1M
- Alexander ChenSaint Louis$951K
- Daniel RosenbluthSaint Louis$903K
- Derek ByersSaint Louis$835K
- Jeffrey AtkinsonSaint Louis$604K
- James KringsSaint Louis$505K
- Colleen McEvoySaint Louis$475K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.